Table 2.
Effectiveness measures.
|
Baseline | Follow-up |
Number and percentage of participants who receive any new vaccine during the study period (eg, participants who accept the first dose of a COVID-19 vaccine, complete the vaccine series, or receive a booster shot) |
|
✓ |
Vaccine hesitancy [32], confidence [43], knowledge [45], attitudes, and beliefs [32] | ✓ | ✓ |
Usability (including acceptability; ie, TT-Ca satisfaction and completion), demand (including the number of youths screened, enrolled, and retained), and practicality (based on the TT-C intervention’s cultural appropriateness and fit) [46] |
|
✓ |
Physical environmental factors (access, utilization, and vaccine misinformation), social environmental factors (discrimination, as measured via the Adapted Everyday Discrimination Scale for Medical Settings [47]; stigma; social support, as measured via the MOSb social support survey [48]; social norms; and medical mistrust, as measured via the Group-Based Medical Mistrust Scale [49]), outcome expectations (COVID-19–specific knowledge, attitudes, and beliefs), observational learning (vaccination [eg, flu or HPVc] experiences of self or others), and perceived self-efficacy (vaccination barriers and facilitators) | ✓ | ✓ |
Sociodemographic characteristics (age, race, ethnicity, gender identity, income, employment, and education [eg, current student]) | ✓ | ✓ |
Pre-existing conditions (eg, diabetes, cardiovascular conditions, etc) | ✓ | ✓ |
aTT-C: Tough Talks for COVID-19.
bMOS: Medical Outcomes Study.
cHPV: human papillomavirus.